• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Authors » Trista Morrison

Trista Morrison

Articles

ARTICLES

Solana Therapeutics Taps LJPC Shell to Give GCS-100 New Life

Jan. 31, 2012
By Trista Morrison
La Jolla Pharmaceutical Co. is anything but new – founded in 1989, the biotech is best known for its rollercoaster ride with lupus drug Riquent (abetimus sodium).
Read More

Infinity Shifts Focus in Wake Of Phase II Hedgehog Failure

Jan. 30, 2012
By Trista Morrison
Shares of Infinity Pharmaceuticals Inc. dropped 40 percent Friday on news that the biotech is stopping development of Hedgehog inhibitor saridegib (IPI-926) in pancreatic cancer after interim data from a Phase II trial showed better survival in the placebo arm.
Read More

Personalized Medicine Gains Ground in Deals, Approvals

Jan. 30, 2012
By Trista Morrison
Two years ago, when the Human Genome Project celebrated its 10th anniversary, scientists across the globe complained the massive sequencing feat had not ushered in an era of personalized medicine as initially promised. Even genomics experts like Francis Collins and J. Craig Venter acknowledged that the field's impact on medical practice has been minimal. (See BioWorld Today, April 5, 2010, and July 6, 2010.)
Read More

GSK Spinout BHV Seeks Funds For Phase II Diabetes Drug

Jan. 27, 2012
By Trista Morrison
Developing diabetes drugs is no easy task. It's even harder if a start-up has to convince venture capitalists it can clear the FDA's high diabetes hurdles. And it's harder still if the FDA has just rejected a drug with the same mechanism of action.
Read More

Dapagliflozin FDA Rejection Not End of SGLT2 Inhibitors

Jan. 23, 2012
By Trista Morrison
The FDA's decision to reject AstraZeneca plc and Bristol-Myers Squibb Co.'s Type II diabetes drug dapagliflozin last week was no surprise, given the drug's spotty safety record and a negative advisory panel vote. But the rejection isn't necessarily a death sentence for dapagliflozin, or for other SGLT2 inhibitors in development.
Read More

Many Formulas for Pharma to Support Start-Ups; J&J Shows

Jan. 20, 2012
By Trista Morrison

Pre-baked exits – in which a big pharma firm helps a venture firm found a new company in exchange for pre-negotiated acquisition rights – are on the rise.


Read More

Like Warren Buffett, J&J Throws Down Incubator Gauntlet . . .Who’s Next?

Jan. 19, 2012
By Trista Morrison
When people talk about Johnson and Johnson’s new San Diego incubator, Janssen Labs, they can’t help but be a little bit skeptical about the fact that J&J isn’t taking any options or first-rights to compounds developed by its incubator tenants. “What’s the catch?” everyone keeps asking. “What does J&J get out of the deal?” I’m guessing J&J execs asked that same question when Diego Miralles, J&J West Coast site head, pitched them on his idea for a no-strings-attached incubator business model. And I’m guessing his answer was something along the lines of “well we’ve got all this expensive equipment and...
Read More

San Diego Scene: Sanford-Burnham Queuing Up Behind J&J to Launch Incubator

Jan. 19, 2012
By Trista Morrison
The San Diego biotech industry has been buzzing this week with the grand opening of Johnson and Johnson’s new incubator, Janssen Labs. But already plans for another San Diego incubator are being laid, this time at the Sanford-Burnham Medical Research Institute. Paul Laikind, Sanford-Burnham’s chief business officer, told BioWorld Today the facility will house six start-ups in an open-lab format similar to the California Institute for Quantitative Biosciences (QB3). Companies will have access to lab space and can use Sanford-Burnham’s 33 core facilities in animal care, high throughput screening, metabolomics or other areas on a pay-as-you-go basis, Laikind said. Unlike...
Read More

2011 Fundraising Tops 2010, Despite Macro, Venture Woes

Jan. 18, 2012
By Trista Morrison
Despite concerns about the economic climate in Europe and whether or not the U.S. is headed into another recession, biotech companies around the world managed to raise $23.4 billion in 2011, up from $19.3 billion in 2010 and almost back on par with the $24.8 billion raised in the glory days of 2007.
Read More

Five New Trends in Biotech Venture

Jan. 17, 2012
By Trista Morrison
The cover story for BioWorld Insight this week is about the biotech venture capital world, and how despite its much-publicized contraction, there’s a lot of exciting stuff going on like established firms closing new funds, established players regrouping to form new firms, and everyone pushing the envelope with experimental business strategies. Although lots of changes are still to come, many of the VCs I spoke with noted how much the biotech venture world has changed already, just over the past few years. A few of their observations: A-B-C No Longer As Easy As 1-2-3: The traditional “Series A – Series...
Read More
View All Articles by Trista Morrison

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe